Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

JAK2V617F activating mutation is associated with the myeloproliferative type of chronic myelomonocytic leukaemia.

Journal of clinical pathology - 1 Sept 2009

Pich A, Riera L, Sismondi F, Godio L, Davico Bonino L, Marmont F, Francia di Celle P

Abstract excerpt

BACKGROUND: Chronic myelomonocytic leukaemia (CMML) is a haematopoietic malignancy with heterogeneous clinical and morphological features. It is classified in the World Health Organization myeloproliferative-myelodysplastic overlap category. JAK2(V617F) mutation can be found in a large percentage...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Biopsy
Share to Bone Marrow
Share to DNA Mutational Analysis

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to DNA, Neoplasm

Share to Janus Kinase 2

Share to Leukemia, Myelomonocytic, Chronic

Share to Leukocyte Count

Share to Platelet Count

Source

Identifiers

PMID: 19734476
DOI: 10.1136/jcp.2009.065904

Genes

JAK2

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026. Prepared record publication-19734476-2026-09-02.2. Manifest publication-graph-cohort-2026-09-02.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

JAK2V617F activating mutation is associated with the myeloproliferative type of chronic myelomonocytic leukaemia.PMID 19734476Read ↗

Chronic myelomonocytic leukemia: myeloproliferative variant.Semantic proximity Read ↗

Myeloproliferative neoplasms and JAK2 mutations.Semantic proximity Read ↗

Incidence and significance of the JAK2 V617F mutation in patients with chronic myeloproliferative disorders.Semantic proximity Read ↗

Pathogenetic role of JAK2 V617F mutation in chronic myeloproliferative disorders.Semantic proximity Read ↗

Chronic Myelomonocytic Leukemia With Fibrosis Is a Distinct Disease Subset With Myeloproliferative Features and Frequent JAK2 p.V617F Mutations.Semantic proximity Read ↗

Janus kinase 2 mutations in Philadelphia negative chronic myeloproliferative disorders: clinical implications.Semantic proximity Read ↗

Analysis of JAK2V617F mutation in Jordanian patients with myeloproliferative neoplasms.Semantic proximity Read ↗

Correlation of JAK2 V617F mutant allele quantitation with clinical presentation and type of chronic myeloproliferative neoplasm.Semantic proximity Read ↗

Morphologic and Molecular Characteristics of De Novo AML With JAK2 V617F Mutation.Semantic proximity Read ↗

A study of JAK2 (V617F) gene mutation in patients with chronic myeloproliferative disorders.Semantic proximity Read ↗

The JAK2V617F tyrosine kinase mutation in myeloproliferative disorders: status report and immediate implications for disease classification and diagnosis.Semantic proximity Read ↗

Clinical significance of V617F mutation of the JAK2 gene in patients with chronic myeloproliferative disorders.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.